WHEREAS, About 25% of Lennox-Gastaut syndrome cases have no
identified cause; and
WHEREAS, Nearly all children with Lennox-Gastaut syndrome
develop learning problems and intellectual disabilities
associated with their frequent seizures; and
WHEREAS, Because the seizures associated with Lennox-Gastaut
syndrome are often resistant to typical treatments, the
resulting intellectual impairments tend to worsen over time; and
WHEREAS, While a person with Lennox-Gastaut syndrome can live
a normal life, more than half of the children with Lennox-
Gastaut syndrome suffer from associated disorders, such as
communication and behavioral issues, trouble with balance and
sleeping, increased instances of rage and aggression and other
issues; and
WHEREAS, Complete recovery is extremely unusual for a child
with Lennox-Gastaut syndrome, and most affected individuals will
need constant support throughout their life; and
WHEREAS, Since there is no cure for Lennox-Gastaut syndrome,
the goal of treatment is to reduce the number of seizures a
person experiences and improve their quality of life with this
disease; and
WHEREAS, The three main treatment options for Lennox-Gastaut
syndrome are antiseizure medications, dietary therapy and other
treatments such as vagus nerve stimulation therapy and surgery;
and
WHEREAS, Further research is needed to identify more
effective therapies; and
WHEREAS, There is still a tremendous amount of work to be
done to understand Lennox-Gastaut syndrome further; and
WHEREAS, November 1 is celebrated worldwide as "International
20230HR0187PN1934 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30